Natera (NTRA)
(Delayed Data from NSDQ)
$129.84 USD
+3.54 (2.80%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $129.82 -0.02 (-0.02%) 7:10 PM ET
3-Hold of 5 3
F Value A Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$129.84 USD
+3.54 (2.80%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $129.82 -0.02 (-0.02%) 7:10 PM ET
3-Hold of 5 3
F Value A Growth A Momentum B VGM
Zacks News
Compared to Estimates, Natera (NTRA) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Natera (NTRA) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Natera (NTRA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Natera (NTRA) delivered earnings and revenue surprises of 56.52% and 21.54%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Biodesix, Inc. (BDSX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Biodesix (BDSX) delivered earnings and revenue surprises of 11.11% and 11.68%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Life Time Group Holdings, Inc. (LTH) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Life Time Group Holdings (LTH) delivered earnings and revenue surprises of 56.25% and 4.53%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FXH
Should iShares Morningstar Small-Cap Growth ETF (ISCG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for ISCG
Earnings Preview: Organon (OGN) Q2 Earnings Expected to Decline
by Zacks Equity Research
Organon (OGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Teladoc (TDOC) Q2 Earnings Navigate BetterHelp Profit Woes?
by Zacks Equity Research
Teladoc's (TDOC) second-quarter results are likely to reflect lower advertising and marketing expenses.
Natera (NTRA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Natera (NTRA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)?
by Zacks Equity Research
Sector ETF report for FXH
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FBT
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
by Zacks Equity Research
Sector ETF report for FBT
Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FXH
Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)?
by Zacks Equity Research
Sector ETF report for FXH
Natera (NTRA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Natera (NTRA) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
What Makes Natera (NTRA) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Natera (NTRA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Compared to Estimates, Natera (NTRA) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Natera (NTRA) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Agilon Health (AGL) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Agilon (AGL) delivered earnings and revenue surprises of -46.43% and 0.72%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Bull of the Day: NeoGenomics (NEO)
by Kevin Cook
Small-cap leader in oncology diagnostics is on sale after patent litigation takes a bite
Enhabit (EHAB) Lags Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Enhabit (EHAB) delivered earnings and revenue surprises of -25% and 1.53%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Bull of the Day: NeoGenomics (NEO)
by Kevin Cook
Diagnostic lab companies were hit by new FDA rules but this cancer fighter rebounds under 3X sales
Natera (NTRA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Natera (NTRA) delivered earnings and revenue surprises of 11.01% and 8.74%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Hold Centene (CNC) Stock for Now
by Zacks Equity Research
Strong membership growth, contract wins, accretive acquisitions and the streamlining of businesses poise Centene (CNC) well for growth.